Akari Therapeutics reported cash from operations of -$3.11M and free cash flow of -$3.11M for the quarter ended Jun 2026, up 4.5% year over year. This cash flow statement covers 37 quarters of results from Dec 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2012 | Mar2014 | Jun2014 | Sep2014 | Dec2014 | Mar2015 | Jun2015 | Sep2015 | Dec2015 | Mar2016 | Jun2016 | Jun2017 | Jun2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Jun2021 | Jun2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||||||
| Net Income | -4.93M | -5.91M | -0.24M | -6.89M | -4.33M | -5.81M | -4.56M | -4.59M | -2.49M | -5.08M | -5.99M | -7.50M | -2.90M | -3.77M | -3.71M | -1.90M | -6.40M | -5.30M | -14.46M | -4.81M | |||||||||||||||||
| Depreciation and Depletion | 0.00M | ||||||||||||||||||||||||||||||||||||
| Share-based Compensation | 0.10M | 0.06M | 0.08M | 0.08M | 0.27M | 0.28M | 0.30M | 0.30M | 0.30M | 0.45M | 0.25M | 1.26M | 1.01M | 0.72M | 0.69M | 0.47M | 0.30M | 0.71M | |||||||||||||||||||
| Deferred Taxes | -0.86M | ||||||||||||||||||||||||||||||||||||
| Asset Writedowns and Impairment | 5.18M | 8.40M | 0.03M | ||||||||||||||||||||||||||||||||||
| Cash from Operations | -7.74M | -4.27M | -0.70M | -4.23M | -4.88M | -4.69M | -2.45M | -4.41M | -4.04M | -4.89M | -1.49M | -2.12M | -2.15M | -3.26M | -2.12M | -3.04M | -2.49M | -3.11M | |||||||||||||||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||||||||||||||
| Amortization of Deferred Charges | |||||||||||||||||||||||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.00M | 0.00M | 986.00 | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M | 0.00M | |||||||||||||||||||||||||||
| Change in Working Capital | |||||||||||||||||||||||||||||||||||||
| Change in Account Payables | |||||||||||||||||||||||||||||||||||||
| Change in Accured Expenses | -1.86M | 0.53M | -0.75M | 1.83M | -0.32M | -0.34M | -0.17M | -0.10M | 1.46M | 1.49M | 0.93M | 1.34M | 0.48M | -0.59M | -0.70M | -0.18M | 0.93M | 0.62M | |||||||||||||||||||
| Other Working Capital Changes | |||||||||||||||||||||||||||||||||||||
| Investing Activities | |||||||||||||||||||||||||||||||||||||
| Capital Expenditures | |||||||||||||||||||||||||||||||||||||
| Cash from Investing Activities | |||||||||||||||||||||||||||||||||||||
| Financing Activities | |||||||||||||||||||||||||||||||||||||
| Other financing activities | 0.19M | ||||||||||||||||||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuances | |||||||||||||||||||||||||||||||||||||
| Long-Term Debt Repayments | |||||||||||||||||||||||||||||||||||||
| Short-Term Debt repayments | 0.21M | 0.33M | 0.34M | 0.22M | 0.11M | 0.17M | 0.17M | 0.06M | 0.10M | 0.15M | |||||||||||||||||||||||||||
| Current Debt | -0.41M | -0.05M | -0.03M | -0.03M | -0.05M | ||||||||||||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||||||||||||||
| Net Equity Issued and Repurchased | 7.10M | 11.96M | 5.99M | 3.21M | 0.29M | 3.51M | -0.13M | 3.13M | 1.09M | -0.76M | 5.55M | 4.85M | 3.00M | ||||||||||||||||||||||||
| Misc. | |||||||||||||||||||||||||||||||||||||
| Cash from Financing Activities | 9.88M | 9.20M | 5.99M | 3.21M | 0.29M | 3.52M | 1.51M | 7.76M | -0.44M | 2.15M | 2.13M | 3.38M | 1.90M | 5.76M | 0.05M | 8.04M | |||||||||||||||||||||
| Exchange Rate Effect | -0.05M | -0.01M | 0.28M | -0.02M | -0.00M | 0.01M | -0.01M | -0.00M | 0.00M | 0.00M | -0.00M | ||||||||||||||||||||||||||
| Change in Cash | 2.09M | 4.92M | -0.43M | 1.74M | -1.67M | -4.40M | -2.45M | -0.89M | -2.54M | 2.87M | -1.93M | 0.41M | -0.02M | 0.13M | -0.23M | 2.72M | -2.44M | 4.93M | |||||||||||||||||||
| Free Cash Flow | -7.74M | -4.27M | -0.70M | -4.23M | -4.88M | -4.69M | -2.45M | -4.41M | -4.04M | -4.89M | -1.49M | -2.12M | -2.15M | -3.26M | -2.12M | -3.04M | -2.49M | -3.11M | |||||||||||||||||||
| Net Cash Flow | 2.14M | 4.93M | -0.70M | 1.76M | -1.67M | -4.40M | -2.45M | -0.89M | -2.53M | 2.87M | -1.93M | 0.03M | -0.02M | 0.12M | -0.22M | 2.72M | -2.44M | 4.93M |
Pull Akari Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=AKTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "AKTX", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=AKTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();